Introduction {#sec0005}
============

Arboviruses are a group of viruses transmitted by arthropod vectors such as *Aedes* spp. mosquitos. Over the last decades, several epidemic arboviral diseases have been reported in areas different from their endemic region (tropics/subtropics; [@bib0355], [@bib0390]) (e.g. [@bib0015], [@bib0030], [@bib0515], [@bib0570], [@bib0670], [@bib0680], [@bib0690], [@bib0695]). The alphavirus chikungunya virus (CHIKV) and the flavivirus Zika virus (ZIKV) are two such arboviruses which have gained attention due to several outbreaks in recent years ([@bib0005], [@bib0105], [@bib0275], [@bib0340], [@bib0375], [@bib0655]). Infections caused by both viruses, although basically asymptomatic, may have severe effects in humans ([@bib0080], [@bib0115], [@bib0290], [@bib0320], [@bib0335], [@bib0535], [@bib0545], [@bib0585], [@bib0615], [@bib0705]), including neurological disorders ([@bib0060], [@bib0075], [@bib0095], [@bib0110], [@bib0120], [@bib0155], [@bib0160], [@bib0435], [@bib0480], [@bib0500], [@bib0540], [@bib0565], [@bib0665]).

Urbanization, globalization, and global warming ([@bib0285], [@bib0430], [@bib0645]) have enhanced the expansion of the *Aedes aegypti* and *Aedesalbopictus* vectors from their geographic origin to other regions, including Europe ([@bib0100]; [@bib0125]; [@bib0165]; [@bib0190]; [@bib0205]; [@bib0270]; [@bib0355]; [@bib0420]; [@bib0550]; [@bib0550]; [@bib0560]; [@bib0580]; [@bib0710]; [@bib0715]). Consequently, three million people are living in *Aedes*-infested regions ([@bib0710]), greatly enhancing the risk for ZIKV and CHIKV infections in areas where the local population is immunologically naïve. Additionally, travel-related cases of ZIKV and CHIKV infection have been reported in Europe ([@bib0050], [@bib0200], [@bib0405], [@bib0510], [@bib0555], [@bib0685], [@bib0700], [@bib0720]), Japan ([@bib0595]), Australia ([@bib0525]), and Israel ([@bib0425]). The 2016 ZIKV epidemic in Brazil, spreading rapidly to other South American countries and North America ([@bib0020], [@bib0130], [@bib0235]; [@bib0650]), also supports this reality. Moreover, autochthonous transmission of CHIKV ([@bib0140], [@bib0175], [@bib0265], [@bib0340], [@bib0660]) and ZIKV ([@bib0440], [@bib0450], [@bib0675], [@bib0725]) has been observed, as well as sexual transmission ([@bib0145], [@bib0150], [@bib0170], [@bib0250], [@bib0415], [@bib0465]), mother-to-child/perinatal transmission ([@bib0055], [@bib0095], [@bib0255], [@bib0485], [@bib0530]), and transmission via blood/platelet transfusion ([@bib0070], [@bib0395], [@bib0445], [@bib0455]). These different ways of transmission/infection put the global population at risk, especially as there is currently no vaccine against ZIKV or CHIKV. It is thus of great importance to develop differential diagnostic tools for the early detection of such infections in order to allow a rapid intervention.

In earlier years, methods developed for the detection of ZIKV and CHIKV were mainly based on serological analyses such as plaque reduction neutralization tests ([@bib0365], [@bib0380], [@bib0590]) and immunoassays such as ELISA tests ([@bib0225]; [@bib0280], [@bib0305], [@bib0330], [@bib0385], [@bib0410], [@bib0600], [@bib0620]). Although these techniques are still useful as they allow detection at a later stage, their clear interpretation is rendered difficult by the fact that cross-reactivity with other arboviruses occurs ([@bib0195], [@bib0230], [@bib0345], [@bib0370]).

In the meantime, molecular based methods have gained interest. They are fast, reliable, specific, allow simultaneous identification and quantification, and are efficient in early diagnosis, as viral RNA can be detected in serum in the first week after the onset of clinical illness, as well as in other sample types, e.g., saliva ([@bib0045], [@bib0460]), urine ([@bib0045], [@bib0260], [@bib0595]), and semen ([@bib0025], [@bib0400]). Several such assays have already been developed for ZIKV/CHIKV ([@bib0040], [@bib0090], [@bib0240], [@bib0490], [@bib0495], [@bib0505], [@bib0520], [@bib0630], [@bib0635]). However, many have been developed for a single region- and/or outbreak-specific strain and thereby lack broad range coverage. Furthermore, they have been developed and published by single laboratories, each using their own experimental conditions, and thus they do not allow a single-plate combination, and specificity studies have often been limited to few other (arbo)viruses. These features make these methods ineffective for a global view of arbovirus diagnosis, and existing methods should thus be adapted or newly designed to allow more straightforward and universal detection.

However, RNA viruses have a high mutation rate ([@bib0180], [@bib0325]), as illustrated by changes in ZIKV ([@bib0135], [@bib0245]) and CHIKV ([@bib0640]) sequences throughout the years/epidemics. These mutations can lead to false-negative results when they occur in the annealing sites of the primers/probes. Next generation sequencing (NGS) allows a high volume of sequence data to be obtained, which can be analysed for mutations ([@bib0035]). This could be used to help in the verification of existing molecular diagnostic methods and the necessary redesign of primer/probes, and thus help improve on current methods by filling in the gaps.

This article reports the development and in-house validation of a new multiplex RT-qPCR TaqMan method designed for the simultaneous detection and discrimination of ZIKV and CHIKV. To circumvent the possibility of obtaining false-negative results due to affected primer/probe annealing sites ([@bib0185], [@bib0360]), two pre-existing methods -- each targeting a different segment in the genomic sequence -- were combined for each virus: nsp4 gene ([@bib0490]) and E gene ([@bib0365]) for CHIKV; M/A genes and E gene ([@bib0370]) for ZIKV. The different method acceptance parameters (specificity, sensitivity, applicability, and practicability) needed to declare a method fit for purpose were evaluated extensively. Additionally, the in silico coverage of a broad range of complete sequences was verified for the first time using whole genome sequencing (WGS) data and a recently developed bioinformatics tool ([@bib0625]).

Materials and methods {#sec0010}
=====================

Selection of primer/probe sets {#sec0015}
------------------------------

Methods detecting ZIKV/CHIKV were selected from the literature based on three criteria: TaqMan technology, amplicon size (50--150 bp), and targeted sequence. The oligonucleotides were subjected to alignment analysis on a limited set of CHIKV/ZIKV sequences retrieved from NCBI, using Clustal Omega ([@bib0215]). Primer/probe sequences were adapted if necessary to allow higher sequence coverage. Subsequently, primer/probe complementarities, melting temperature (Tm), and self-annealing were evaluated for each method using Multi Primer Analyzer software with standard settings ([@bib0610]).

Methods passing this selection stage were tested in a singleplex assay in a primer/probe concentration titration experiment (five primer/probe concentration combinations) using positive reference materials specific for the virus under analysis ([Table 1](#tbl0005){ref-type="table"} ). Methods that performed well (i.e., positive reaction on the specific reference materials and no reaction on the negative control, lowest quantification cycle (Cq) value with lowest primer/probe concentration) were combined into a two-plex assay per virus (acceptance criterion: similar performance as the singleplex) and then into the final four-plex assay. The procedure followed is explained in [Figure 1](#fig0005){ref-type="fig"} .Table 1Materials used and specificity results using the four-plex RT-qPCR method.Table 1SpeciesTypeStrainOriginExpected signalObtained signalCHIKVZIKVCHIKVZIKVVirusesChikungunyaRNAS27 Petersfield strain[a](#tblfn0005){ref-type="table-fn"}AmpliRun® Chikungunya Virus RNA Control; Labconsult (Vircell)+−+−La Reunion -- 2006CIBU+−+−ROSSciensano (Viral Diseases)+−+−ZikaRNAMR766 strain (African)[a](#tblfn0005){ref-type="table-fn"}AmpliRun® Zika Virus RNA Control; Labconsult (Vircell)−+−+PRVABC59 strain (Asian)AmpliRun® Zika Virus (Asian Lineage) RNA Control; Labconsult (Vircell)−+−+7630 Cote d'Ivoire -- 1980CIBU−+−+Strain H/PF/2013 (clinical isolate) -- French Polynesia 2013Sciensano (Viral Diseases)−+−+Dengue serotype 1RNAHawaii strainAmpliRun® Dengue 1 Virus RNA Control; Labconsult (Vircell)−−−−DENV1 -- Hawaii (sngt vero cells)CIBU−−−−Dengue serotype 2RNANew Guinea C strainAmpliRun® Dengue 2 Virus RNA Control; Labconsult (Vircell)−−−−DENV2 -- New Guinea (sngt vero cells)CIBU−−−−Dengue serotype 3RNAH87 strainAmpliRun® Dengue 3 Virus RNA Control; Labconsult (Vircell)−−−−DENV3 -- Pat H Birmanie (sngt vero cells)CIBU−−−−Dengue serotype 4RNAH241 strainAmpliRun® Dengue 4 Virus RNA Control; Labconsult (Vircell)−−−−DENV4 -- 63632 Birmanie (sngt AP61)CIBU−−−−Tick-borne encephalitisRNANeudorfl strainAmpliRun® Tick Borne Encephalitis Virus RNA Control; Labconsult (Vircell)−−−−TBEV -- LangatCIBU−−−−TBEV -- HyprCIBU−−−−TBEV -- NeudorflSciensano (Viral Diseases)−−−−TBEV -- AbsettarovSciensano (Viral Diseases)−−−−West NileRNANew York-99 strainAmpliRun® West Nile Virus RNA Control; Labconsult (Vircell)−−−−WNV -- Souche 143 -- lineage 1CIBU−−−−WNV -- Camargue 2002 -- lineage 1CIBU−−−−WNV -- New York 99 -- lineage 1Sciensano (Viral Diseases)−−−−WNV -- lineage 2Sciensano−−−−Yellow feverRNA17D strainAmpliRun® Yellow Fever Virus RNA Control; Labconsult (Vircell)−−−−Asibi strainCIBU−−−−FNVCIBU−−−−17D strainCIBU−−−−Japanese encephalitisRNAJEV -- genotype 1CIBU−−−−JEV -- Nakayama (genotype III)Sciensano (Viral Diseases)−−−−St Louis encephalitisRNA/AmpliRun® St Louis Encephalitis Virus RNA Control; Labconsult (Vircell)−−−−Western equine encephalitisRNAH160/99 strainAmpliRun® Western Equine Encephalitis RNA Control; Labconsult (Vircell)−−−−Eastern equine encephalitisRNAH178/99 strainAmpliRun® Eastern Equine Encephalitis RNA Control; Labconsult (Vircell)−−−−Parainfluenza 1RNAC-35 strainAmpliRun® Parainfluenza 1 RNA Control; Labconsult (Vircell)−−−−Influenza A H1RNAA/Brisbane/59/2007AmpliRun® Influenza A H1 RNA Control; Labconsult (Vircell)−−−−Influenza BRNAB/Brisbane/60/2008AmpliRun® Influenza B RNA Control; Labconsult (Vircell)−−−−RhinoRNA1059 strainAmpliRun® Rhinovirus RNA Control; Labconsult (Vircell)−−−−CoronaRNA229E STRAINAmpliRun® Coronavirus RNA Control; Labconsult (Vircell)−−−−Bacteria*Streptococcus salivarius*DNASubsp. *salivarius* Andrewes and HorderLGC (ATCC® 9759D5™)−−−−*Actinomyces naeslundii*DNAThompson and LovestedtLGC (ATCC® 12104D5™)−−−−*Lactobacillus jensenii*DNAGasser et al.LGC (ATCC® 25258D™)−−−−*Lactobacillus gasseri*DNALauer and KandlerLGC (ATCC® 33323D5™)−−−−*Staphylococcus epidermidis*DNA(Winslow and Winslow) EvansLGC (ATCC® 35984D5™)−−−−*Staphylococcus aureus*DNASubsp. *aureus* RosenbachLGC (ATCC® 700699D5™)−−−−*Streptococcus agalactiae*DNALehmann and NeumannLGC (ATCC® BAA611D5™)−−−−*Listeria monocytogenes*DNA53 XXIII strainAmpliRun® Listeria Monocytogenes DNA Control; Labconsult (Vircell)−−−−*Salmonella enteritidis*DNACDC K-1891 strain (subspecies *enterica*)AmpliRun® Salmonella Enteritidis DNA Control; Labconsult (Vircell)−−−−*Salmonella typhi*DNA/AmpliRun® Salmonella Typhi DNA Control; Labconsult (Vircell)−−−−*Escherichia coli* (VTEC)DNA/AmpliRun® Escherichia Coli (VTEC) DNA Control; Labconsult (Vircell)−−−−Yeast/fungi*Candida albicans*DNA(Robin) Berkhout(ATCC® 14053D™)−−−−*Aspergillus versicolor*DNABCCM/IHEM 1994Sciensano (IHEM/BCCM collection, Mycology and Aerobiology)−−−−*Aspergillus fumigatus*DNAMCV-C\#10 strainAmpliRun® Aspergillus Fumigatus DNA Control; Labconsult (Vircell)−−−−Parasites*Giardia intestinalis*DNAWB clone C6AmpliRun® Giardia Intestinalis DNA Control; Labconsult (Vircell)−−−−DNA(Lambl) AlexeieffLGC (ATCC® 50803D™)−−−−*Cryptosporidium parvum*DNAStrain IowaLGC (ATCC® PRA67™)−−−−*Entamoeba histolytica*DNASchaudinnLGC (ATCC® 30459D™)−−−−HumanHumanDNA/Thermo Fisher Scientific−−−−[^4][^5]Figure 1Overview of the workflow used to (A) select the RT-qPCR methods and develop the four-plex method and (B) validate the four-plex RT-qPCR method.Figure 1

Materials and extraction {#sec0020}
------------------------

Reference RNA and DNA materials were purchased or obtained from sample collections ([Table 1](#tbl0005){ref-type="table"}).

The QCMD 2016 Zika Virus EQA Pilot Study consisted of 10 samples: two ZIKV-negative sample (one containing CHIKV), seven ZIKV-positive samples (four African, three French Polynesian), and one mixed sample (composed of dengue virus serotype 2 (DENV-2), West Nile virus (WNV), and yellow fever virus (YFV)). Serum, saliva, and urine samples were collected during the 2016 outbreak in New Caledonia by Institut Pasteur de Nouvelle-Calédonie (IPNC) and in 2017 in French Guiana by Institut Pasteur de la Guyane (IPG) from patients presenting symptoms possibly due to a ZIKV/CHIKV infection.

RNA from proficiency test and serum/saliva/urine samples was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) and MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche), respectively.

One-step RT-qPCR {#sec0025}
----------------

All reactions were performed on a CFX96 Touch™ instrument (Bio-Rad) using the SuperScript III Platinum One-Step Quantitative RT-PCR System (Invitrogen) according to the manufacturer's instructions. A final reaction volume of 25 μl containing 5 μl template was used. The following cycling conditions were applied: a cDNA synthesis cycle 15 min/50 °C, a hold step 2 min/95 °C, and subsequently 45 cycles of denaturation 15 s/95 °C and annealing/elongation 30 s/60 °C. Nuclease-free water was used as the no-template control (NTC).

Detailed information concerning the oligonucleotides used (Eurogentec) is given in [Table 2](#tbl0010){ref-type="table"} .Table 2Primer/probe sets and final concentrations used in the four-plex RT-qPCR method, as well as reference amplicons for each method as used in the SCREENED analysis.Table 2Primer/probe nameSequence (5′ → 3′)Target sequenceAmplicon size (bp)Location on reference genome[a](#tblfn0010){ref-type="table-fn"}Final concentration (nM)Ref.Target: CHIKVCHIKV-a-F\
CHIKV-a-R\
CHIKV-a-PTGATCCCGACTCAACCATCCT\
GGCAAACGCAGTGGTACTTCCT\
FAM-TCCGACATCATCCTCCTTGCTGGC-BHQ-1Nsp183241--323600\
600\
300[@bib0490])Reference amplicon: TGATCCCGACTCAACCATCCTGGATATTGGTAGTGCGCCAGCAAGGAGGATGATGTCGGACAGGAAGTACCACTGCGTTTGCCCHIKV-b-F\
CHIKV-b-R\
CHIKV-b-PTCACTCCCTGTTGGACTTGATAGA\
TTGACGAACAGAGTTAGGAACATACC\
HEX-AGGTACGCGCTTCAAGTTCGGCG-BHQ-1E11266856--6981800\
800\
400[@bib0365])Reference amplicon: TCACTCCCTGTTGGACTTGATAGAGGCTGCTTTCGGAGAGATTTCCAGCTGTCATCTACCGACAGGTACGCGCTTCAAGTTCGGCGCCATGATGAAATCTGGTATGTTCCTAACTCTGTTCGTCAATarget: ZIKVZIKV-a-F\
ZIKV-a-R\
ZIKV-a-PTTGGTCATGATACTGCTGATTGC\
CCYTCCACAAAGTCCCTATTGC\
TEX-CGGCATACAGYATCAGGTGCATWG\
GAG-BHQ-2M/A77941--1017600\
600\
300Adapted from [@bib0370])Reference amplicon: TTGGTCATGATACTGCTGATTGCCCCGGCATACAGTATCAGGTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGZIKV-b-F\
ZIKV-b-R\
ZIKV-b-PYCGYTGCCCAACACAAG\
CCACYAAYGTTCTTTTGCAGACAT\
Cy5-AGCCTACCTTGACAAGCARTCAGACA\
CTCAA-BHQ-2E771192--12681000\
1000\
500Adapted from [@bib0370])Reference amplicon: TCGTTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACATTAGTGG[^6][^7]

Generation of an RNA standard {#sec0030}
-----------------------------

The regions targeted by the two ZIKV and CHIKV methods were amplified from the respective reference materials ([Table 1](#tbl0005){ref-type="table"}) and cloned into the pBluescript II SK+ plasmid (GeneCust). Additionally, a genetically modified (GM) plant sequence ([@bib0220]) was cloned into the plasmid. The presence of the DNA inserts was confirmed by Sanger sequencing.

The plasmid was linearized by digestion with *Spe*I. The target sequences were amplified using the TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. The in vitro transcribed RNA was treated with DNAse to digest the plasmid and was then purified using the GeneJET RNA Purification Kit (Thermo Fisher Scientific). The RNA was quantified on a Qubit 3.0 Fluorometer (Thermo Fisher Scientific).

Method acceptance parameters {#sec0035}
----------------------------

The specificity of the four-plex assay was tested in two replicates on a list of materials, as shown in [Table 1](#tbl0005){ref-type="table"}. The RT-qPCR conditions were as described above. For materials where the copy number was known, a dilution of 200 cp/μl was used; for other materials a 1:10 and 1:100 dilution was used. Based on the literature, the Cq cut-off was set at 38. The sensitivity of the assay was determined for each method of the multiplex on a specific material ([Table 1](#tbl0005){ref-type="table"}) by preparing a dilution series (1000, 100, 50, 10, 5, 1, 0.1 cp) in nuclease-free water and measuring each dilution two-fold in two independent runs under repeatability conditions ([@bib0315]). Using samples from a proficiency test (QCMD 2016 Zika Virus EQA Pilot Study) and routine samples, all tested in duplicate, the parameters applicability and practicability were evaluated.

Use of the bioinformatics tool {#sec0040}
------------------------------

Coverage of the ZIKV and CHIKV genome sequences by the four chosen methods (individually and in duplex) was analysed using the SCREENED web tool ([@bib0625]) with default advanced options. A config file containing the oligonucleotide and reference amplicon sequences ([Table 2](#tbl0010){ref-type="table"}) was used for the analysis. As the reference amplicon sequence input in SCREENED is a codon DNA strand, the CHIKV-a probe, originally designed to anneal to the anti-codon DNA strand, was introduced as its reverse complement. Full-length nucleotide sequences for ZIKV were retrieved from the NCBI Virus Resource database (5/11/2017) allowing for any host, region/country, genome region, and isolation source; and for CHIKV from the [@bib0475] Nucleotide database using '"Chikungunya virus"\[porgn:\_\_txid37124\] AND "complete genome"' as keywords (5/11/2017). The accession numbers retrieved for both viruses are available as Supplementary material (Tables S1 and S2).

Results {#sec0045}
=======

Development of a new four-plex RT-qPCR method {#sec0050}
---------------------------------------------

For CHIKV, all four RT-qPCR methods that complied with the set criteria showed good sequence coverage and no oligonucleotide adaptations were necessary. The subsequent analysis showed a good performance for all four methods, as no primer/probe complementarities or self-annealing properties were detected and Tm values complied with standard PCR rules. In the titration experiment, two CHIKV methods performed well and were combined to form a duplex.

For ZIKV, a similar procedure was followed. Four of the five retrieved methods were adapted after the alignment analysis to cover for genetic variation. All five, together with an in-house designed method, showed a good performance in the subsequent analysis. Based on the titration experiment, three methods were discarded (late Cq values for all primer/probe concentrations). The three remaining methods (all adapted from the literature) were combined into three duplex assays, of which one showed the best results.

The two duplex assays, complying with the set criterion, were combined into a four-plex assay, which was subjected to the validation process evaluating the necessary acceptance parameters ([Figure 1](#fig0005){ref-type="fig"}); the optimal primer/probe concentrations that resulted from the titration experiment were used ([Table 2](#tbl0010){ref-type="table"}).

Due to the limitation to four fluorophores, no internal control was added to the reaction. However, an external positive (and negative) control should always be included. The constructed RNA standard gave a specific positive reaction with the multiplex assay for all four methods and could thus be used effectively as a positive control. The cloned soybean 356043 GM plant sequence ([@bib0220]) allows testing for contamination; i.e., when a presumed negative control reacts positively with the ZIKV/CHIKV multiplex, running a PCR with the GM-specific primers/probes and its specific cycling programme will allow to determine whether the positivity comes from a contamination with the plasmid.

In-house validation of the new multiplex RT-qPCR method {#sec0055}
-------------------------------------------------------

To ensure a new PCR method is fit for purpose, a number of method acceptance parameters should be tested, such as the specificity and sensitivity, at the very least (cf MIQE guidelines ([@bib0085])). As no specific guidelines are available for RT-qPCR methods for virus detection, the in-house validation was based on a combination of the methods reported by Saunders et al. ([@bib0575]) and Broeders et al. ([@bib0065]) and the basic specificity principles of ISO 22118 ([@bib0310]) and ISO 16140 ([@bib0010]).

Specificity {#sec0060}
-----------

For all four methods, all strains of the respective positive reference materials showed a clear specific amplification ([Table 1](#tbl0005){ref-type="table"}; [Figure 2](#fig0010){ref-type="fig"} ). None of the non-target-containing materials gave a specific amplification ([Table 1](#tbl0005){ref-type="table"}). This list included RNA from arboviruses (different strains) other than ZIKV and CHIKV, RNA from respiratory viruses showing similar symptoms upon infection, human DNA, DNA from bacteria commonly/possibly present in saliva ([@bib0350]), DNA from bacteria and yeast putatively found in the urinary tract ([@bib0295]), and DNA from a few other microorganisms ([@bib0310], [@bib0010]). Additionally, no unspecific hits were returned in the in silico test (data not shown) performed for each method, first against its counterpart (CHIKV methods versus ZIKV database and vice versa) and subsequently as MegaBlast against the entire NCBI database without any specification for species.Figure 2Amplification curves obtained in the specificity test for each of the four methods constituting the new multiplex RT-qPCR method. For readability of the graphics, a selection of tested materials was made: dengue serotype 1-4, CHIKV, West Nile virus, Yellow Fever virus, St Louis encephalitis virus, Eastern Equine encephalitis virus, Western Equine encephalitis virus, Influenza A H1, Influenza B (all reference materials from Labconsult (Vircell)), ZIKV, Japanese encephalitis virus, Tick borne encephalitis virus (all materials received form CIBU), *Streptococcus salivarius*, *Lactococcus jensenii* (both ATCC materials obtained from LGC) and NTC.Figure 2

Sensitivity {#sec0065}
-----------

The sensitivity of the multiplex method was assessed via the determination of the limit of detection (LOD) of each of the methods when used as a four-plex. The LOD of each run was set at the lowest copy number at which both replicates were still positive (Cq cut-off = 38), and the LOD of the method was established as the highest LOD over the two runs. According to this, the LOD was set at 5 cp and 50 cp for the CHIKV-a and CHIKV-b methods, respectively, and at 100 cp for both ZIKV methods ([Table 3](#tbl0015){ref-type="table"} ).Table 3Results of the sensitivity test for the four-plex RT-qPCR method for the detection of ZIKV and CHIKV.Table 31000 cp100 cp50 cp10 cp5 cp1 cp0.1 cpNTCCHIKV-a28.2--28.231.9--31.533.3--32.935.2--35.9*35.7--36.1*40.3--NDND--NDND28.4--28.532.2--32.233.2--33.135.8--35.7*36.8--36.0*38.6--NDND--NDNDCHIKV-b30.1--30.035.0--34.0*35.8--36.1*ND--NDND--NDND--NDND--NDND28.3--28.431.9--31.5*33.0--33.8*36.3--NDND--NDND--NDND--NDNDZIKV-a31.9--32.635.1--35.8*37.6--36.6*ND--NDND--NDND--NDND--NDND32.1--32.1*34.8--34.5*35.7--NDND--NDND--NDND--NDND--NDNDZIKV-b32.0--33.2*36.3--36.9*38.4--38.039.1--39.9ND--NDND--NDND--NDND33.3--33.2*37.3--37.4*38.2--38.240.1--NDND--NDND--NDND--NDND[^8]

Applicability and practicability {#sec0070}
--------------------------------

To show the applicability of this multiplex RT-qPCR method, it was tested on different matrices: the reference materials used for the development, the plasmid positive control, the samples from the QCMD proficiency test, and routine serum/saliva/urine samples collected from patients suspected to be infected with ZIKV/CHIKV ([Table 4](#tbl0020){ref-type="table"} ). A correct outcome was obtained for all materials, i.e., exponential-shaped amplification curves and Cq \<38 for CHIKV/ZIKV-containing matrices, and an unspecific curve and Cq \>38 considered as negative for non-ZIKV/CHIKV materials.Table 4Results of the ZIKV/CHIKV four-plex RT-qPCR method on real-life samples.Table 4Sample origin (suspected infection)SerumUrineSalivaZIKV-aZIKV-bCHIKV-aCHIKV-bZIKV-aZIKV-bCHIKV-aCHIKV-bZIKV-aZIKV-bCHIKV-aCHIKV-bIPNC (ZIKV)+ (35.7)ND− (42.2)− (38.9)+ (31.4)+ (35.1)NDND+ (28.4)+ (29.8)+ (41.2)NDIPNC (ZIKV)+ (35.9)NDNDND+ (25.8)+ (28.9)NDND+ (29.8)+ (31.1)NDNDIPG (ZIKV)NDNDNDND+ (32.0)+ (32.4)NDND+ (36.7)+ (37.6)NDNDIPG (CHIKV)NDND+ (18.6)+ (25.9)////////IPG (CHIKV)NDND+ (18)+ (27.2)////////[^9]

Concerning practicability, the fact that four methods were combined into one already renders it very time and cost efficient. Additionally, due to the use of the one-step RT-qPCR kit, the method is easy to apply in a routine laboratory, as it can be set up as a simple PCR reaction not needing any additional instrument/infrastructure or training of staff.

Sequence coverage of the multiplex method {#sec0075}
-----------------------------------------

For CHIKV, 521 full-length genomes were retrieved and the predictive SCREENED analysis showed that 99.8% and 97.1% were covered by CHIKV-a and CHIKV-b, respectively. CHIKV-a was expected to detect all genomes except KX168429.1 (Asia) due to a two-nucleotide mismatch at the very 3′ end of the reverse primer. CHIKV-b showed slightly smaller in silico inclusivity, but it was predicted to detect genome KX168429.1, while the 15 genomes not detected by CHIKV-b were recognized by CHIKV-a. When the two methods were combined, 100% of the retrieved genomes were thus predicted to be detected ([Table 5](#tbl0025){ref-type="table"} ).Table 5Evaluation of CHIKV and ZIKV RT-qPCR methods using the SCREENED web tool. The first column shows the method name. The second column shows the total number of genomes analysed per method. The third, fourth, and fifth columns show the numbers of genomes detected, numbers of genomes not detected, and numbers of genomes where the amplicon could not be retrieved, respectively. The sixth column shows the percentage for the in silico inclusivity per method and per duplex.Table 5Method nameNumber of genomes analysedNumber of genomes detectedNumber of genomes not detectedNumber of genomes no amplicon found% in silico inclusivityCHIKV-a5215201099.8CHIKV-b52150615097.1CHIKV duplex52152100100.0ZIKV-a4784744099.2ZIKV-b47846117096.4ZIKV duplex4784762099.6[^10]

A total of 478 complete ZIKV genome sequences were selected and both ZIKV-a and ZIKV-b methods performed well, with an in silico inclusivity of 99.16% and 96.44%, respectively. In duplex, only two genomes were predicted to be undetected. For genome KF383115 (Africa), this was due to one nucleotide mismatch within the 3′ end of the reverse primer in both methods. If one mismatch is allowed in this region, or if the length of the 3'end region sensitive to nucleotide mismatches is set at 4 (instead of the default value of 5), this genome would be detected by both methods. Genome KF383118 (Africa) was predicted to be undetected by both ZIKV-a (because of one nucleotide mismatch in the 3′ end of the forward primer-template duplex) and ZIKV-b (because of a nucleotide mismatch of the last nucleotide in the 3′ end of the reverse primer-template duplex). If two mismatches are allowed in this critical region, this genome would be detected by both methods.

Discussion {#sec0080}
==========

Rapid, reliable, and early diagnosis is of great importance to enable the correct treatment to be applied for infected individuals and, perhaps even more importantly, to contain the spread of the infection.

Although several RT-qPCR methods for arbovirus detection have been developed, they have some drawbacks for application in a multi-target screening environment: they have often been designed based on a single region/outbreak-specific strain, using particular run conditions, and validation has most often been tested in a restricted way. Parameters such as specificity, sensitivity, practicability, and applicability, often lacking or poorly addressed in the literature, are needed to declare a newly developed method fit for purpose. These parameters should be systematically included in the process of method development; for example, see Broeders et al. and Saunders et al. ([@bib0065], [@bib0575]). Such method validation, according to well-defined criteria, increases the efficiency of diagnosis as it enables easy method transfer between laboratories, allowing worldwide harmonization.

To exploit the PCR technology in a more efficient way and to meet the current needs in arbovirus detection -- i.e., effectiveness, reliability, transferability, and universal application -- a new four-plex RT-qPCR assay for the simultaneous detection and discrimination of ZIKV and CHIKV was developed and thoroughly validated in-house. The assay is specific: it only detects the different strains of the targeted arboviruses and none of the non-target materials, including organisms that may be present simultaneously with the infective arbovirus. A sensitivity of 5--100 cp was obtained, which is comparable to the individual original methods. The method can be efficiently applied on proficiency test and routine serum/saliva/urine samples. This is of great importance in view of eventually using non-invasive samples to circumvent the current necessity of venous blood collection. It has indeed already been demonstrated that arboviruses are present in samples other than serum, e.g., saliva ([@bib0460], [@bib0470], [@bib0605]), urine ([@bib0210], [@bib0260], [@bib0300]), and semen ([@bib0045]). It is worth establishing this further on a larger set of samples. The positive detection in these samples also supports the fact that the four-plex method is applicable on strains from different regions/outbreaks.

The plasmid, which was developed in parallel and can be used as a positive control, is easily multipliable; this therefore eliminates the need to buy expensive control material or to purify it in high concentration from viruses for which specific confinement/biosafety conditions need to be taken into account.

The use of two independent target sequences for each virus enhances the reliability of the assay, as false-negative results for the first method due to the occurrence of mutations can be covered by the second method. Indeed, using the SCREENED tool it was shown, for example, that genome KX168429.1, which is undetected by CHIKV-a, is covered by its counterpart CHIKV-b; this proves the added value of designing RT-qPCR methods on two distinct targets for the same virus.

Bio-informatics analysis, as presented here for the first time, using the SCREENED tool, further demonstrates the possible detection of a wide number of strains emerging in different regions and from different outbreaks. This analysis, important for the worldwide application of a detection method, can never be performed so extensively in a laboratory. However, the tool only gives an indication of the performance of an (RT-q)PCR method and laboratory testing is still required. For example, it cannot be excluded that the method will work in practice on genome KF383115, which is undetected by the two ZIKV methods due to a mismatch located in the fifth last nucleotide of the 3′ end of the primer.

The analysis of a large amount of WGS data (obtained via NGS) using the SCREENED tool could further help to verify the performance of the existing molecular diagnostic methods. The observed genetic variability and the detection of mutations could lead to the modification of primers/probes, thereby providing highly universal methods that are applicable on the different occurring strains/isolates and thus helping to cover the gaps (i.e., poor inclusivity) in the current methods.

Overall, the results show the validity of this multiplex RT-qPCR method. The combination of the four chosen methods allows the detection of the specific viruses in different sample types without cross-reactivity and this can easily be implemented in routine settings as a first step in the differential diagnosis of arbovirus infections.

(RT-)qPCR is an easy, user-friendly technique, making it an ideal tool to be implemented at point-of-care (POC) facilities. The development of countertop PCR instruments (e.g., Genesystem Genechecker; Roche Diagnostics Cobas Liat PCR System; Mediphos GenePOC revogene platform; Cepheid GeneXpert) that are affordable, small, easy to operate, run on site, have fast turnaround times, and even include the extraction step, which is often a critical point when working in the field, will prompt early diagnosis, leading to quicker decision-making. The further development of other arbovirus-specific multiplex methods, using the same RT-qPCR one-step kit and cycling conditions as the CHIKV/ZIKV one described here, will aid in building up a multi-target one-plate panel usable in screening analysis, allowing the detection of different targets in an efficient manner and a shorter time. If, in addition, a full in-house validation is performed, the transfer of these methods could enable worldwide harmonization.

This progress, together with extended prevention and information campaigns (e.g., use of social media), will lead to the better and faster control and management of arbovirus infections -- and by extension other diseases -- which in turn could improve patient health, reduce the risk of transmission, and potentially lower mortality and morbidity, as well as allow worldwide surveillance.
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